Etamivan

Etamivan

Etamivan

Chemical compound

Etamivan (INN, or ethamivan (USAN); trade names Analepticon, Emivan, and Vandid) is a respiratory stimulant drug[1] related to nikethamide. It was mainly used in the treatment of barbiturate overdose[2] and chronic obstructive pulmonary disease,[3] but has now largely fallen into disuse.

Quick Facts Clinical data, Trade names ...

Adverse effects which are common to the respiratory stimulant class include sneezing, coughing, and laryngospasm when infused too rapidly. More serious adverse events include muscle twitching, tremors, and convulsions. The dose to treat barbiturate intoxication or carbon dioxide narcosis in adults ranges from 0.5 mg/kg to 5.0 mg/kg, infused intravenously over several minutes. Epilepsy and the use of monoamine oxidase inhibitors or other adrenergic drugs are contraindications.[4]

References

  1. [1]
    Hirsh K, Wang SC (May 1975). "Respiratory stimulant effects of ethamivan and picrotoxin". The Journal of Pharmacology and Experimental Therapeutics. 193 (2): 657–63. PMID 1173598.
  2. [2]
    Wheeldon PJ, Perry AW (July 1963). "The use of ethamivan in the treatment of barbiturate poisoning". Canadian Medical Association Journal. 89 (1): 20–2. PMC 1921664. PMID 14000228.
  3. [3]
    Sproule BJ, Jans RL, Breitkreutz H, Mahon W (December 1964). "Effects of ethamivan in patients with chronic respiratory disease". Canadian Medical Association Journal. 91 (23): 1203–8. PMC 1928498. PMID 14226094.
  4. [4]
    American Medical Association Dept of Drugs (1977). AMA Drug Evaluations (3rd ed.). Littleton, Mass.: Pub. Sciences Group. p. N-61. ISBN 978-0-88416-175-2. OCLC 1024170745.


Stub icon

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Etamivan, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.